{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-23-000070","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.689578+00:00","generated_at":"2026-06-15T09:15:29.795416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Caribou Q1 net loss $28M, cash $291M; CB-010 dose expansion enrolling, CB-011 dosing initiated","bullets":["Net loss of $28.0M in Q1 2023, vs $19.1M in Q1 2022, driven by higher R&D expenses.","Cash and equivalents $291.0M as of March 31, 2023; cash runway into 2025.","R&D expenses rose to $25.7M (Q1 2023) from $13.9M (Q1 2022) to advance pipeline.","CB-010 ANTLER trial enrolling second-line LBCL in dose expansion; plan to report data H2 2023.","CB-011 CaMMouflage Phase 1 dosing at dose level 1 for r/r multiple myeloma; IND for CB-012 planned H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-23-000070","json":"https://secwatch.observer/filing/0001619856-23-000070.json","markdown":"https://secwatch.observer/filing/0001619856-23-000070.md","text":"https://secwatch.observer/filing/0001619856-23-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000070/0001619856-23-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000070/crbu-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:15:29.795416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"942501a5b41f5cfbf70cd7d699ee71da688ef2e1","claim":"Caribou Biosciences, Inc. reported three months ended March 31, 2023 results: revenue $3.5 million, net income $28.0 million net loss.","evidence_excerpt":"First Quarter 2023 Financial Results Cash, cash equivalents, and marketable securities: Caribou had $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023, compared to $317.0 million as of December 31, 2022. Caribou expects its cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plan into 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.5 million for the three months ended March 31, 2023, compared to $2.7 million for the same period 2022. The increase was primarily due to revenue recognized under the Collaboration and License Agreement with AbbVie and other license agreements. R&D expenses: Research and development expenses were $25.7 million for the three months ended March 31, 2023, compared to $13.9 million for the same period in 2022. The increase was primarily due to costs to advance pipeline programs, including the ANTLER and CaMMouflage","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985623000070/0001619856-23-000070-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Revenue","value":"$3.5 million"},{"label":"Net income","value":"$28.0 million net loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}